Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.64 |
| ▸ | KLK7 | P49862 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | KYNU | Q16719 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870038 | 1.00 | KLK5 (0.64) | KLK5KLK7PPARACACNA1BSYK | |
| SCHEMBL14300984 | 1.00 | KLK5 (0.64) | KLK5KLK7PPARACACNA1BSYK | |
| SCHEMBL12585497 | 0.94 | KLK5 (0.65) | KLK5KLK7PPARACACNA1BSYK | |
| SCHEMBL10585294 | 0.94 | KLK5 (0.65) | KLK5KLK7PPARACACNA1BSYK | |
| SCHEMBL4370045 | 0.94 | KLK5 (0.65) | KLK5KLK7PPARACACNA1BSYK | |
| SCHEMBL9943561 | 0.94 | KLK5 (0.65) | KLK5KLK7PPARACACNA1BSYK | |
| SCHEMBL9943562 | 0.94 | KLK5 (0.65) | KLK5KLK7PPARACACNA1BSYK | |
| SCHEMBL344670 | 0.91 | PPARA (0.63) | KLK5KLK7PPARACACNA1BSYK | |
| SCHEMBL344669 | 0.91 | PPARA (0.63) | KLK5KLK7PPARACACNA1BSYK | |
| SCHEMBL84710 | 0.91 | PPARA (0.63) | KLK5KLK7PPARACACNA1BSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-04-09 | — | — | US | disclosed |
| EP-4587443-A1 | MACROCYCLIC CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2025-07-23 | — | — | EP | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2024056798-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-03-21 | — | — | WO | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022194399-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-22 | — | — | WO | disclosed |
| WO-2008022365-A2 | COMPOSITIONS FOR INFLUENCING THE EFFECTS OF ORGANOPHOSPHORUS COMPOUNDS AND USE OF GALANTHAMINE, ITS DERIVATIVES AND ANALOGUES FOR PRODUCING SUCH COMPOSITIONS | SANOCHEMIA LTD. (MT) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | CFTR, CLIC1, ARRB1 | KLK5 4024/4885KLK7 3862/4885PPARA 2255/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | KLK5 3192/4885KLK7 3334/4885PPARA 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.